NeurAxis Reports Strong Fourth Quarter and Full Year 2025 Financial Results
Neuraxis, Inc. (NRXS)
Company Research
Source: GlobeNewswire
CARMEL, Ind., March 19, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the fourth quarter period and full year ended December 31, 2025. 4Q25 Financial Highlights Revenues increased 27% year over year to $968 thousand in 4Q25.Operating loss increased 17% year over year, primarily due to higher selling expenses directly related to increased sales volume and compensation expenses to facilitate growth. Cash balance was $5.0 million as of December 31, 2025. FY2025 Financial Highlights Revenues for FY2025 increased 33% year over year to $3.6 million.Operating loss increased 9% year over year, primarily due to a one-time non-recurring legal settlement. Excluding the legal settlement, the Company’s operating loss was flat year over year despite its investment in selling
Show less
Read more
Impact Snapshot
Event Time:
NRXS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NRXS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NRXS alerts
High impacting Neuraxis, Inc. news events
Weekly update
A roundup of the hottest topics
NRXS
News
- NeurAxis (NRXS) had its price target raised by Craig Hallum from $8.00 to $13.00. They now have a "buy" rating on the stock.MarketBeat
- Neuraxis Inc (NRXS) Q4 2025 Earnings Call Highlights: Revenue Growth Amidst Operational Challenges [Yahoo! Finance]Yahoo! Finance
- NeurAxis to Host Fourth Quarter and Full Year 2025 Results and Business Update Call on Thursday, March 19, 2026 [Yahoo! Finance]Yahoo! Finance
- NeurAxis to Host Fourth Quarter and Full Year 2025 Results and Business Update Call on Thursday, March 19, 2026GlobeNewswire
- NeurAxis Achieves Major Milestone with AMA Category I CPT® Code Now in Effect, Establishing a Permanent Reimbursement PathwayGlobeNewswire
NRXS
Sec Filings
- 3/19/26 - Form 10-K
- 3/2/26 - Form 4
- 2/26/26 - Form 4
- NRXS's page on the SEC website